Aim-To investigate the influence of bilirubin on the surface tension activity of a porcine derived (Curosurf) and synthetic (Exosurf) surfactant.
used.
Results-Curosurf (without bilirubin) showed a higher surface tension activity than Exosurf, as shown by area compression of 30 (SD 0.6)% compared with 76(1.4)% at low surfactant dose and 25 (0.9)% compared with 85 (0.5)% at high dose (P<0.01). Bilirubin showed negligible surface activity at the concentrations studied. At low phospholipid dose (0.5 mglml Curosurf), bilirubin increased film area compression of lipid extract surfactant from 30 (0.6)% to 55 (1.6)%, 59 (0.1)%, and 68 (0.5)% at the three studied bilirubin concentrations, respectively (P<0.01). At high phospholipid dose (1 mg/ml Curosurf), bilirubin had the same adverse, although less pronounced, effect on film area compression of porcine lipid extract surfactant (25 (0.9)% vs 26 (0.9)%, 39 (1.3)%, and 44 (1.1)%, respectively) (P<0.01). Using synthetic surfactant (Exosurf), with a much lower original surface activity, bilirubin did not further inhibit its surface tension properties at any of the phospholipid doses studied. Conclusion-These results indicate that in vitro bilirubin impairs the surface tension activity ofporcine lipid extract surfactant, but does not affect synthetic surfactant activity.
(Arch Dis Child 1996;75:F191-F196) Keywords: bilirubin, surfactant, surface tension, respiratory distress syndrome.
The intratracheal administration of exogenous surfactant in infants with respiratory distress syndrome (RDS) reduces the severity of respiratory distress and neonatal mortality.'2 Although a variety of lipid extract and synthetic surfactants are therapeutically effective, 5 to 30% of infants with RDS do not respond favourably to surfactant treatment.3 4 Most interest in hyperbilirubinaemia in neonates has focused on the toxic effects of bilirubin on the central nervous system.5 By contrast, little work has been directed at other organ systems where high serum concentration of bilirubin might have a pathogenetic role. In very low birthweight infants with RDS and hyperbilirubinaemia, bilirubin can enter the alveolar space in fluid leaking from capillaries, where its presence at necropsy has been called "yellow hyaline membrane disease."6 However, there is little information on whether this entity reflects disordered surface activity of surfactant in vivo and in vitro. Preliminary studies have focused on the effect of acidosis on bilirubin-lipid extract surfactant interaction. 7 However, it is well known that the inhibiting effects of plasma proteins on surfactant in vitro are most pronounced at low surfactant concentrations and that this effect can be reversed by increasing surfactant concentrations.89 Other plasma components, such as bilirubin, acting by different mechanisms, may exhibit different patterns of concentration dependent surfactant inhibition. 10 The paucity of data on this topic prompted us to perform a series of experiments with the captive bubble surfactometer (CBS)" to characterise the effects of different bilirubin concentrations on the surface tension lowering properties oftwo commercially available surfactant preparations: porcine lipid extract (Curosurf) and synthetic surfactant (Exosurf). In accordance with previous reports, we focused our study on the compression of film area required to achieve minimum surface tension because this is a much more sensitive criteria of possible inhibitory effect of bilirubin on surfactant surface activity than the minimum surface tension.'2 The biophysical results of this study will provide new insights into the in vitro effects of bilirubin on pulmonary surfactant activity. They may also have therapeutic implications for the clinical management of RDS in preterm babies with hyperbilirubinaemia.
Methods
Two surfactant preparations in current clinical use were investigated. Curosurf (Chiesi Company, Parma, Italy) is a lipid extract surfactant isolated from minced pig lungs using a sequence of washing, centrifugation, chloroform-methanol extraction and liquid gel chromatography. It contains about 99% polar lipids, mainly phospholipids (30-35% dipalmitoylphosphatidylcholine or DPPC) and 1% hydrophobic proteins (SP-B and SP-C) in an approximate molar ratio of 1:2. " Curosurf was supplied as a suspension in unbuffered physiological saline with a phospholipid concentration of 80 mg/ml.
Exosurf (Burroughs-Wellcome Reinach, Basel, Switzerland) is a synthetic surfactant consisting of DPPC, hexadecanol, and tyloxapol in a proportion of 13.5/1.5/1 mg/ml.
Exosurf is a lyophilised powder that was reconstituted as a suspension according to the manufacturer's instructions.
Both surfactant preparations were stored at -20'C until use. After the phial was opened to remove the amount of surfactant needed for a series of experiments during a period of about 4 hours the phial was immediately capped and stored at 2-3'C for a maximum of three days. For the experiments, phospholipid concentration in the samples was adjusted to 0.5 mg/ml and 1 mg/ml by adding 0.9% NaCl. Greater lipid concentrations could not be studied, in as much as discerning the edges of the bubbles in the presence of bilirubin was too difficult, the suspensions being too murky. Independent experiments were performed using both surfactant preparations alone, which served as control group.
Crystalline bilirubin (Sigma Chemical Co, St Louis, MO, USA) was dissolved in 0.05M NaOH and buffer at pH 7.4. For all experiments with bilirubin the final measured pH in the solution was 7.35. Bilirubin solutions were prepared, protected from light, and added to the cited surfactant solutions, in a ratio of 1:1 to 1:4, such that the final bilirubin concentrations were 0.25 mg/ml, 0.5 mg/ml, and 1.0 mg/ml. The ratio was estimated considering surfactant pool size and bilirubin concentration in the monolayer of immature lungs after adsorption. ' For adsorption measurements (ST-max), a 20-gauge needle (flat tip) was introduced through the bottom inlet of the chamber. The needle tip was moved up to within 1 cm of the agarose ceiling, and the needle was held in this position by friction. Stirring was started at this point and continued during the adsorption period. A 6 to 7 mm in diameter bubble was then formed by turning the focusing knob of the microscope stand by about 90' as quickly as possible. The transition time for the bubble formation from the first appearance of air at needle tip to the resting position at the agarose ceiling, was < 0.17 seconds, as measured by counting single frames on the television monitor. After this interval, the bubble has assumed a Laplacian shape ( Adsorption for synthetic surfactant was slower than that for lipid extract surfactant, reaching a plateau value between 34 and 37 mN/m, and was not influenced by bilirubin at any chosen concentration and phospholipid dose. Adsorption (5 minutes) of Curosurf in the presence of bilirubin was mainly affected at low phospholipid dose of 0.5 mg/ml, giving higher surface tensions above 33 mN/m compared with about 24 mN/m for Curosurf controls. At higher Curosurf doses (1.0 mg/ ml), the effect on adsorption in the presence of bilirubin was less pronounced, giving significant values above 31 mN/m only at the higher bilirubin concentration of 1.0 mg/ml, compared with about 25 mN/m for Curosurf controls. Significant differences in maximum surface tension (after 5 minutes of adsorption) After equilibrium surface tension was reached, static cycles were performed by increasing the pressure in the sample chamber stepwise, as already described.
Minimum surface tension (ST-min) was obtained when the bubble either ceased to decrease in height or when the bubble suddenly clicked during compression in small steps. 2122 Minimum surface tensions were substantially higher than the control values, but only for Curosurf at low phospholipid dose (0.5 mg/ml) in combination with bilirubin at high concentration (1 mg/ml). The minimum surface tension obtained after the adsorption period for low dose Curosurf in the presence of 1 mg/ml bilirubin was 9.9 (2.0) mN/m, showing the greatest inhibition of surface activity compared with control experiments and experiments using synthetic surfactant.
Minimum surface tensions returned to the normal range (3.2 (0.5) mN/m) at high phospholipid concentration showing that the influence of bilirubin on surface tension properties of lipid extract surfactant is dose dependent. In contrast to lipid extract surfactant, minimum surface tension of synthetic surfactant was not affected by bilirubin at any chosen concentration (table 2) . Figures 1 and 2 show the effect of increasing bilirubin concentrations on area compression (AC) required to achieve the above mentioned minimum surface tension for both surfactant preparations at different phospholipid concentration.
Synthetic surfactant films have to be compressed far more to achieve minimum surface tension than lipid extract surfactant films (area compression, control experiments: 30(0.6)% for Curosurf vs 76 (1.4)% for Exosurf in the low dose group and 25 (0.9)% vs 85 the high dose group. Furthermore, us extract surfactant (0.5 mg/ml), increa compression is required to achieve minimum surface tensions in the presence of bilirubin (55 (1.6)%, 59 (0.10)%, and 68 (0.5)% at 0.25, 0.5, and 1.0 mg/ml bilirubin concentrations, respectively). At high Curosurf dose (1 mg/ml) this effect was still present but less pro-** nounced (26 (0.9)%, 39 (1.3)%, and 44 (1.1)% at 0.25, 0.5, and 1.0 mg/ml bilirubin, respectively) (P<0.01 vs controls for the last two values), indicating a negative correlation between surfactant inhibition by bilirubin and surfactant concentration in the solution (fig 1) . In contrast, this detrimental effect of bilirubin on the surface activity of lipid extract surfactant could not be observed using In recent in vitro studies, using the captive bubble method, 18 it has been shown that, whereas the effects of serum proteins on minimum surface tension were similar to those reported by others, the per cent reduction in film area required to achieve minimum surface tension is a much more sensitive measure of the effect of surfactant inhibiting substances on surface activity than is the measure of minimum surface tension.
In our experiments surface tension was reduced by compressing the film area in a quasi-static manner until minimum surface tension was achieved. At low phospholipid concentration (0.5 mg/ml), bilirubin had the most impressive effect on natural surfactant stability, showing a dose-effect relation between surfactant and bilirubin concentrations. Surfactant films initially compressed by only about 30% had to be compressed by 75% to reach near zero tensions after adding bilirubin. This effect was shown, but in a less pronounced manner, at higher phospholipid dose (1 mg/ml) where the film area reduction necessary to reach minimum surface tension changed from 25% to about 50%.
In control experiments synthetic surfactant films had to be compressed by 80 to 85% to reach near zero tensions after repeated cycling, showing a smaller surface tension lowering capacity of synthetic surfactant than lipid extract surfactant.
The question is why bilirubin impairs the activity of porcine lipid extract surfactant (Curosurf) and not that of synthetic surfactant (Exosurf). Figures 1 and 2 show that standard Exosurf has lower surface activity than standard Curosurf and its performance is not influenced by bilirubin. Differences in the chemical composition of the two surfactant preparations could be responsible for the different results. Exosurf is a mixture of DPPC, a high molecular alcohol and a non-ionic detergent.
In a recent study Findlay et al" showed that the non-DPPC components of synthetic surfactant may have a cytotoxic effect on alveolar type II cells. Non-ionic detergents, like tyloxapol, are commonly used in the laboratory to induce haemolysis. It is possible that alcohol and/or the detergent of synthetic surfactant "neutralise" the adverse effect of bilirubin on the DPPC layer at the air-liquid interface, which is the essential component of surfactant surface activity. However, more attractive is the hypothesis that there is a biochemical interaction between bilirubin and the specific surfactant proteins SP-B and/or SP-C which results in an impaired surface activity of lipid extract surfactant. Considering the different components of pulmonary surfactant, this last hypothesis could explain the different conclusions of our study from those of Notter et al. '" Further studies are needed to determine whether surfactant associated proteins (SP-B and/or SP-C) are coupled or inactivated by bilirubin during adsorption, spreading, or squeeze-out.
In vitro, the detrimental effect ofbilirubin on Curosurf can be overcome by an increase in surfactant concentration. This observation could suggest that the same dose-effect is operative in vivo. However, such an extrapolation must be verified by well designed animal and clinical studies, in that the chemical environment in peripheral air spaces is much more complex. Additional effects of bilirubin on the lungs under different physical conditions are possible. Nevertheless, our in vitro observations might have practical implications for clinical management of jaundice in babies with RDS treated with exogenous surfactant and in babies with meconium aspiration syndrome. 28 In conclusion, our in vitro study suggests a more aggressive approach to neonatal hyperbilirubinaemia in the presence of RDS or a more aggressive approach to RDS in babies with hyperbilirubinaemia and treated with lipid extract surfactant is warranted. Further studies are needed to document in vivo, in animal experiments with induced hyperbilirubinaemia, the influence of bilirubin on lung finction. Furthermore, the biochemical mechanisms of the detrimental effect of bilirubin on surface activity of lipid extract surfactant need to be elucidated.
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